Eli Lilly and Company (LLY)

Return on equity (ROE)

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	US$ in thousands	10,590,000	5,240,400	6,244,800	5,581,700	6,193,700
Total stockholders’ equity	US$ in thousands	14,192,100	10,771,900	10,649,800	8,979,200	5,641,600
ROE		74.62%	48.65%	58.64%	62.16%	109.79%

December 31, 2024 calculation

ROE = Net income ÷ Total stockholders’ equity
= $10,590,000K ÷ $14,192,100K
= 74.62%

Eli Lilly and Company's Return on Equity (ROE) has shown fluctuations over the past five years. Starting at a high of 109.79% on December 31, 2020, Eli Lilly experienced a significant decline to 62.16% by the end of 2021. This downward trend continued into 2022 and 2023, with ROE values of 58.64% and 48.65% respectively. However, there was a notable improvement in the company's ROE in 2024, reaching 74.62%.

The declining trend in ROE from 2020 to 2023 may raise concerns about the company's ability to generate profits from shareholders' equity efficiently. However, the rebound in 2024 could indicate improved profitability or better utilization of equity. It will be essential for stakeholders to monitor future ROE values to assess Eli Lilly's performance in generating returns for its shareholders.